A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (goserelin acetate implant) 10.8 mg and ZOLADEX® (goserelin acetate implant) 3.6 mg in Chinese Patients with Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

Trial Identifier: D8664R00001
Sponsor: AstraZeneca
NCTID:: NCT03193060
Start Date: September 2017
Primary Completion Date: December 2019
Study Completion Date: December 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China
China shijiazhuang, China